Interleukin-6 in Patients with Cardiac Myxoma

• Published in: Journal of the College of Physicians and Surgeons--Pakistan Vol. 30; no. 8; pp. 849 - 852
• Main Authors: Yuan, Shi-Min, Lin, Hui-Zhen
• Format: Journal Article
• Language: English
• Published: College of Physicians and Surgeons Pakistan 01.08.2020
• Subjects: Care and treatment; Health aspects; Interleukin-6; Myxoma; Patient outcomes; Risk factors; China
• ISSN: 1022-386X; 1681-7168
• DOI: 10.29271/jcpsp.2020.08.849

The relationships between interleukin (IL)-6 and cardiac myxoma remain to be clarified. This article systematically reviewed the IL-6 properties in cardiac myxoma patients based on retrieval of pertinent literature published between 1998 and 2018. Significant differences were found in circulating IL-6 values between preoperation and 1 and 6 months after operation. Preoperative circulating IL-6 correlated significantly with tumour volume (r=0.8552, p=0.003), while there were no significant correlations with maximal tumour dimension (r=0.2443, p=0.190). No correlation was found between circulating IL-6 at 1 and 6 months after tumour resection with either tumour volume or with maximal tumour dimension. The positive rate of immunostaining of IL-6 in cardiac myxoma tissues was 93.3%. Overproduction of IL-6 is responsible for the inflammatory presentations, constitutional symptoms, and recurrence and distal embolisation of cardiac myxoma. Cardiac myxoma could be a cellular source of IL-6 release. Cardiac myxoma resection is an absolute choice of eliminating IL-6 production in these patients. Key Words: Cardiac surgical procedures, Cytokines; Inflammation, Interleukin-6, Neoplasms.